Media headlines about Cancer Genetics (NASDAQ:CGIX) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cancer Genetics earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 45.3228660742075 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
CGIX has been the topic of a number of analyst reports. Maxim Group initiated coverage on Cancer Genetics in a research report on Thursday, December 7th. They set a “buy” rating and a $6.00 price objective on the stock. ValuEngine cut Cancer Genetics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Zacks Investment Research raised Cancer Genetics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 29th. Finally, HC Wainwright set a $6.00 price objective on Cancer Genetics and gave the company a “buy” rating in a research report on Tuesday, February 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $5.56.
Shares of Cancer Genetics stock traded down $0.10 on Friday, reaching $1.80. The company had a trading volume of 126,163 shares, compared to its average volume of 115,291. The company has a market cap of $49.87, a P/E ratio of -1.86 and a beta of 1.24. Cancer Genetics has a 52 week low of $1.55 and a 52 week high of $5.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.01 and a quick ratio of 2.01.
About Cancer Genetics
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.